ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

NVLN Novelion Therapeutics Inc

0.68
0.00 (0.00%)
10 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Novelion Therapeutics Inc NASDAQ:NVLN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.68 0.63 0.6677 0 01:00:00

Initial Statement of Beneficial Ownership (3)

15/01/2020 10:26pm

Edgar (US Regulatory)


FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Broadfin Healthcare Master Fund Ltd
2. Date of Event Requiring Statement (MM/DD/YYYY)
1/9/2020 

3. Issuer Name and Ticker or Trading Symbol

NOVELION THERAPEUTICS INC. [NVLNF]
(Last)        (First)        (Middle)

20 GENESIS CLOSE, ANSBACHER HOUSE, SECOND FLOOR, P.O. BOX 1344
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          ___X___ 10% Owner
_____ Officer (give title below)        _____ Other (specify below)
(Street)

GRAND CAYMAN, E9 KY1-1108      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Shares 2541222 D (1) 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Warrants  (2) (2)COMMON SHARES  (2) (2)D (1) 

Explanation of Responses:
(1) The securities are held in the account of Broadfin Healthcare Master Fund, Ltd., a private investment fund managed by Broadfin Capital, LLC and may be deemed to be beneficially owned by Kevin Kotler, managing member of Broadfin Capital, LLC. Each of Broadfin Capital, LLC, Broadfin Healthcare Master Fund, Ltd. and Kevin Kotler (collectively, the "Reporting Persons") disclaim beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and affirmatively disclaim being a "group" for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act").
(2) Broadfin Healthcare Master Fund, Ltd. owns 909,296 warrants with a strike price of $4.40 which expire on 3/16/2022. The warrants may not be converted if, after such conversion, the Reporting Person would beneficially own, as determined in accordance with Section 13(d) of the Act, more than 9.99% of the Common Shares outstanding immediately after giving effect to such conversion.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Broadfin Healthcare Master Fund Ltd
20 GENESIS CLOSE, ANSBACHER HOUSE
SECOND FLOOR, P.O. BOX 1344
GRAND CAYMAN, E9 KY1-1108

X

Broadfin Capital, LLC
300 PARK AVENUE, 25TH FLOOR
NEW YORK, NY 10022

X

KOTLER KEVIN
C/O BROADFIN CAPITAL, LLC
300 PARK AVENUE, 25TH FLOOR
NEW YORK, NY 10022

X


Signatures
BROADFIN HEALTHCARE MASTER FUND, LTD., By: /s/ Kevin Kotler, Director1/15/2020
**Signature of Reporting PersonDate

BROADFIN CAPITAL, LLC, By: /s/ Kevin Kotler, Managing Member1/15/2020
**Signature of Reporting PersonDate

/s/ Kevin Kotler1/15/2020
**Signature of Reporting PersonDate

1 Year Novelion Therapeutics Chart

1 Year Novelion Therapeutics Chart

1 Month Novelion Therapeutics Chart

1 Month Novelion Therapeutics Chart

Your Recent History

Delayed Upgrade Clock